Pacira's long-acting pain drug advancing

En route to a potential FDA approval next month, Pacira Pharmaceuticals ($PCRX) reports data from previous trials of its lead drug Exparel for postsurgical pain. In patients who had surgery to enlarge their breasts and took the drug, there were no signs of ill effects in healing or breast appearance 13 months and two years after their surgeries. The data were presented on Sept. 24 at the annual American Society of Plastic Surgeons meeting in Denver. The FDA is expected to complete its review of the drug for postsurgical pain and decide whether to give it a market green light by Oct. 28. Exparel consists of the approved drug bupivacaine and is encased in liposome particles that enable the active ingredient to be released gradually. Release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.